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The role of DNA cytosine methylation, an epigenetic regulator of chromatin structure and function, during normal and
pathological brain development and aging remains unclear. Here, we examined by MethyLight PCR the DNA methylation
status at 50 loci, encompassing primarily 59 CpG islands of genes related to CNS growth and development, in temporal
neocortex of 125 subjects ranging in age from 17 weeks of gestation to 104 years old. Two psychiatric disease cohorts—
defined by chronic neurodegeneration (Alzheimer’s) or lack thereof (schizophrenia)—were included. A robust and progressive
rise in DNA methylation levels across the lifespan was observed for 8/50 loci (GABRA2, GAD1, HOXA1, NEUROD1, NEUROD2,
PGR, STK11, SYK) typically in conjunction with declining levels of the corresponding mRNAs. Another 16 loci were defined by
a sharp rise in DNA methylation levels within the first few months or years after birth. Disease-associated changes were limited
to 2/50 loci in the Alzheimer’s cohort, which appeared to reflect an acceleration of the age-related change in normal brain.
Additionally, methylation studies on sorted nuclei provided evidence for bidirectional methylation events in cortical neurons
during the transition from childhood to advanced age, as reflected by significant increases at 3, and a decrease at 1 of 10 loci.
Furthermore, the DNMT3a de novo DNA methyl-transferase was expressed across all ages, including a subset of neurons
residing in layers III and V of the mature cortex. Therefore, DNA methylation is dynamically regulated in the human cerebral
cortex throughout the lifespan, involves differentiated neurons, and affects a substantial portion of genes predominantly by
an age-related increase.
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INTRODUCTION
Epigenetic modification of chromatin, including DNA methylation
at the sites of CpG dinucleotides, is a key regulator of gene
expression, growth and differentiation in virtually all tissues,
including brain [1,2,3,4]. Dysregulated DNA methylation, or
methyl-CpG-dependent chromatin remodeling, is thought to
underlie ICF syndrome (Immunodeficiency, Centromere instability
and Facial anomalies), Rett’s disorder and other mental retarda-
tion syndromes [5,6]. Furthermore, changes in methylation status
at selected genomic loci may affect social cognition [7], learning
and memory [8] and stress-related behaviors [9] and is believed to
contribute to dysregulated gene expression in a range of adult-
onset neuropsychiatric disorders, including autism, schizophrenia,
depression and Alzheimer’s disease [10,11,12,13,14]. Finally, there
is strong evidence that aberrant methylation of tumor suppressor
genes contributes to the molecular pathology of a subset of
astrogliomas and other types of brain cancers [15,16].
However, despite its clinical importance, the regulation of DNA
cytosine methylation, particularly in the human brain, remains
poorly understood. To date, there are no comprehensive studies
which have monitored methylation at multiple loci during the
course of brain development and aging, or in chronic psychiatric
disease. Furthermore, all previous studies of DNA methylation in
human or animal brain utilized tissue homogenates comprised of
a highly heterogeneous mixture of neurons and glia [8,9,12,17], or
examined DNA methylation in subfractions of chromatin defined
by site-specific histone modifications [18] and therefore it remains
to be determined whether or not DNA methylation is dynamically
regulated in terminally differentiated neurons.
Given this background, the present study was undertaken to
provide a first insight into the dynamics of DNA methylation in
the human cerebral cortex. Altogether, we examined 50 loci,
mostly CpG islands within the 59 end of genes, during the course
of development, maturation and aging. Additionally, we assessed
the methylation status for these same loci in Alzheimer’s disease
and schizophrenia; the former condition is characterized by
chronic neurodegeneration and the latter by widespread tran-
scriptional and metabolic perturbations [19,20,21] in the absence
of large scale loss of neurons. While disease-associated alterations
were limited to 2/50 sequences in the Alzheimer’s cohort of the
present study, the majority of genomic loci, including genes
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a striking age-associated increase in methylated CpGs. Further-
more, we show that DNA methylation is dynamically regulated in
differentiated neurons during the transition from childhood to
advanced age. Collectively, our results suggest that DNA
methylation in the human cerebral cortex, including its neuronal
constituents, is dynamically regulated across the full lifespan and
potentially affects a substantial portion of the genome.
RESULTS
Four types of age-related DNA methylation profiles
in the human cerebral cortex
Using a real-time PCR-based technique called MethyLight
[22,23], we analyzed DNA methylation at 50 loci, most of them
representing promoter CpG islands of genes expressed in the
cerebral cortex; a portion of these genes is also implicated in
cancer biology (Table S1 and Table S2). Most of the cancer-
related genes included in this study show aberrant methylation in
various types of neoplasia, including CNS tumors (Table S1), and
hence we were interested to monitor potential methylation
changes within these genes during the course of normal brain
development and aging. Other genes included in this study play
a role in the molecular pathology of some cases diagnosed with
schizophrenia and other psychiatric illness (e.g., BDNF, DRD2,
GABRA2, GAD1, HOXA1, NTF3) or are linked to chronic
neurodegeneration (LDLR, PSEN1, S100A2). We screened alto-
gether 125 pre- and postnatal, child and adult samples of rostro-
lateral temporal cortex, yielding 7,500 quantitative measurements
(Fig. 1). Two of the CpG islands (AR and FAM127A) are from X-
linked genes, which become methylated only on the inactive X-
chromosome in females, and were included as internal controls to
validate the DNA methylation measurements (Fig. 1). For 124
(out of 125) samples, AR and FAM127A methylation levels were in
agreement with the gender information provided by the brain
bank, and for the remaining one case, the discrepancy was
resolved upon re-review of the chart on file with the bank.
Therefore, all of the female postmortem samples, but none of the
males, showed substantial DNA methylation of both of these X-
linked genes, as expected.
Unsupervised hierarchical clustering of the remaining 48 gene
loci, excluding the X-linked genes, revealed a strong age
association (Fig. 1). All prenatal samples were contained in
a single cluster, shown at the top of Fig. 1 (blue cluster). The
subjects over 40 years of age were divided into two other major
clusters with either moderate amounts (red cluster at bottom) or
high density of CpG island methylation (black cluster in middle).
The majority of loci showed a statistically significant increase of
DNA methylation associated with age, adjusted for diagnosis, but
the chronology of these age-associated changes varied remarkably
among different loci. Altogether, four different types of age-related
methylation changes were discernible: (1) Eight of the 50 gene loci
showed a linear increase of DNA methylation with age, as
exemplified by HOXA1 (Fig. 2 and Figure S1). (2) Half of the
genomic loci showed a statistically significant biphasic age
distribution (Figure S1). Among these, 18 genes revealed a sharp
shift in slope at some time-point within the first decade of life,
mostly in the newborn period, as indicated by PAX8 (Fig. 2 and
Figure S1). (3) One locus (MGMT) showed a highly unusual, non-
linear stochastic accumulation of hypermethylation starting at
about age 50 (Fig. 2 and Figure S1). The stochastic nature of this
hypermethylation event is of particular interest, since variation in
MGMT CpG island hypermethylation in gliomas is associated with
clinical response to alkylating agents [24]. Interestingly, the
incidence of malignant gliomas peaks around age 40–50 [25,26],
which is the same age period when MGMT hypermethylation
emerged in the samples of the present study. (4) Finally, in striking
contrast to the age-related progressive increase in DNA methyl-
ation at single copy genes (described above under type 1,2,3), ALU
and other repetitive elements either showed a significant decrease in
DNA methylation during the first decade of life, followed by
relatively little change during subsequent maturation and aging
(1/5 repetitive sequences) (Fig. 2), or showed relatively little
change across the lifespan (4/5 repetitive sequences) (Figure S1).
For the majority of loci showing an age-related increase in DNA
methylation, the effect was extremely robust (p,0.0001) (Fig. 2
and Figure S1).
While it was beyond the scope of this study to assess the
relationship between the observed age-related methylation pattern
and corresponding changes in gene expression for all loci, we
hypothesized that genes showing a linear and robustly progressive
increase in methylation throughout the lifespan (‘‘type 1’’ genes,
see above and Fig. 2) would show a decline in mRNA levels at
advanced age. To examine this, we profiled temporal cortex
mRNA levels by qRT-PCR for 4 of the ‘‘type 1’’ genes listed in
Fig. 2 (SYK, NEUROD2, GABRA2, GAD1) in a cohort of six child
brains (range: 1.3–11.5 years) and 11 adults (range: 32–87 years),
carefully matched for RNA quality (see Methods) and normalized
to 18S rRNA levels (data not shown). Indeed, all four genes
showed an inverse correlation between mRNA levels and age, to
a moderate degree (R
2=0.29–0.42 for SYK, NEUROD2, GAD1
and GABRA2). In contrast, mRNA levels of B2M and GUSB, two
housekeeping genes commonly used to assess RNA quality in
human postmortem specimens [27], and of MGMT–a gene with
a highly unusual age-related methylation profile (Fig. 2)–did not
show a correlation with age (R
2=0.02 for MGMT, and ,0.002 for
B2M and GUSB). Therefore, the age-related decline in mRNA
levels observed for a subset of the ‘‘type 1’’ genes is not explained
by generalized RNA deficit or decay in the older specimens. We
conclude that the progressive, age-related increases in DNA
methylation at the 59 sequences of these genes could contribute to
the observed age-related decline in corresponding mRNA levels.
Disease-associated alterations
Taking a false discovery rate into account, Alzheimer’s cases
showed a statistically significant difference in DNA methylation for
SORBS3 and S100A2. In both cases, the Alzheimer patients tend to
show an acceleration of the age-associated changes in DNA
methylation (Fig. 3). SORBS3 (also known as vinexin, SCAM-1 or
SH3D4), which encodes a cell adhesion molecule expressed in
neurons and glia [28], becomes progressively more likely to be
methylated with age, and is methylated to a greater degree in
Alzheimer patients (median PMR=38.5, N=18) than in all other
cases (schizophrenia, controls) older than 60 years (median
PMR=16.9, N=39, P=0.00081). S100A2, a member of the
S100 family of calcium binding proteins, displays a complex
chronology, with a rapid prenatal increase, followed by an
infrequent stochastic decrease in DNA methylation later in life,
particularly among Alzheimer patients (median PMR=12.9,
N=18) versus all other subjects older than 60 years (median
PMR=20.5, N=39, P=0.00197). The age- and disease-associ-
ated loss of S100A2 DNA methylation in Alzheimer’s disease is
consistent with the observation of S100A2 protein in corpora
amylacea, or polyglucosan bodies, which accumulate in aging
human brains [29]. Therefore, the significant DNA methylation
changes in Alzheimer’s disease, including the decrease of S100A2
and increase in SORBS3 CpG methylation, appear to represent
accelerations of the normal, age-associated DNA methylation
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e895Figure 1. DNA methylation changes at 50 loci in temporal neocortex across the lifespan. Two dimensional hierarchical cluster analysis using
Manhattan distance and average linkage (N=48 regions, 125 subjects). DNA (rostro-lateral temporal neocortex) was extracted and analyzed by
MethyLight for the genes indicted as described (see Methods). Each gene is grouped into quartiles (Dark Light Blue=1 low, Dark Blue=2 medium-
low, Red=3 medium high, Black=4 high extent of methylation). The larger the number of samples with no detectable methylation, the fewer the
number of observations coded dark blue and red. Gender (Blue squares=Male, Pink circles=Female), Age (White circles=Prenatal (PRE); Gray
circles=0–40 years old; Black circles=older than 40 years), and Diagnosis (Green circles=controls; Blue triangles=Schizophrenia cases; Red
squares=Alzheimer’s cases) are indicated with symbols explained below each variable. AR and FAM127A are two additional X-linked genes with DNA
methylation occurring on the inactive X-chromosome in females, and are dichotomized at a PMR value of 20, as indicated. PMR=Percent of
Methylated Reference [23,55]. Three major sample clusters are indicated on the right hand side in blue (consisting mostly of prenatal and young adult
samples), black, consisting mostly of subjects over 40 years old with high density CpG island methylation, and red, mostly subjects over 40 years old
with lower density CpG island methylation.
doi:10.1371/journal.pone.0000895.g001
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evidence that DNA methylation is involved in transcriptional
regulation of PSEN1 [10] an Alzheimer’s disease-associated gene
and regulator of amyloid precursor protein and Notch signaling
pathways [30]. However, PSEN1 showed only very low levels of
methylation in our samples, and we did not find age- or disease-
associated changes (Table S3, part a). This lack of consistent
change in PSEN1 methylation in diseased or aging tissue,
however, may not be surprising given that this gene exhibits
significant variability in interindividual methylation, according to
a study in male germ cells [31].
The methylation of PAX8, a gene encoding a paired box-
containing transcription factor important for CNS and thyroid
development [32], was higher in schizophrenics than in controls
(P=0.0025) (Table S3, part b), but this was not considered
statistically significant after adjusting for multiple comparisons by
controlling the false discovery rate (set at 0.05) [33]. We conclude
that schizophrenia is not accompanied by consistent DNA
methylation changes at the 50 gene loci included in this study.
The de novo DNA methyltransferase, DNMT3a, is
expressed in developing and aging cerebral cortex
The DNA methylation data described above strongly suggest that
DNA methylation events in the cerebral cortex are ongoing across
a wide age range, extending beyond the developmental period and
continuing into old age. If this hypothesis is correct, then one
would expect expression of the de novo DNA methyltransferase
enzymes, DNMT3a and/or DNMT3b [34,35], at all ages. In
mouse cerebral cortex, Dnmt3a expression remains detectable in
adults, albeit at lower levels than observed during earlier periods of
postnatal development; in contrast, Dnmt3b is found in murine
Figure 2. Four developmental profiles for cortical DNA methylation. (A) Associations of log-transformed PMR values (ln(PMR+1); y-axis) with age (x-
axis) for several representative genes. Trends are studied using linear regression. HOXA1 shows a linear association. MGMT-M2B shows a non-linear
shift, with the P-value referring to a T-test of the difference in mean methylation value for subjects under or over 50 years of age. For the biphasic
linear trends of PAX8 and the ALU sequence ALU-M1B (Table S2) , the P-values refer to a test of change of slope. Green dots=controls, blue
triangles=schizophrenia and red squares=Alzheimer’s subjects. (B) Schematic summary of the four different types (1–4, see text for details) of
developmental methylation profiles in human temporal cortex across the lifespan (x-axis, B=birth), as illustrated by the representative examples in
(A). (C) Listings and proportion of gene loci (total=48; excluding AR and FAM127A which showed gender-specific methylation) that show significant
age-dependent methylation changes: colors refer to the scheme in (B). Gray sector refers to the subset of loci without a significant age effect. N=125
subjects. All p-values are adjusted for diagnosis; *** p,0.0001, ** p,0.001, * p,0.05.
doi:10.1371/journal.pone.0000895.g002
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To find out when DNMT3a protein is expressed in the human
cerebral cortex, we employed immunoblotting on cortical
homogenates from fetal, child and adult samples. We observed,
across all ages, an immunoreactive band of approximately
120 kDa, corresponding to full-length form of DNMT3a [37,38]
(Fig. 4A). Immunolabeling of intact nuclei from child and adult
cortex revealed that the bulk of the DNMT3a-like immunoreac-
tivity is derived from neuronal nuclei (Fig. 4B–E). Expression of
DNMT3a in neurons was confirmed by in situ hybridization
studies with full length DNMT3a cRNA (Fig. 4F–H); a subset of
neurons, including some with pyramidal neuron-like morphology
(Fig. 4G) residing in layers III and V of the adult cortex expressed
DNMT3a mRNA. We conclude that DNMT3a in human
cerebral cortex is expressed primarily in neurons, which is in
agreement with similar findings in mice [36] and, furthermore, is
expressed across the lifespan from the 2
nd trimester of pregnancy
through old age.
Age-related DNA methylation changes in nuclei of
differentiated neurons
Notably, studies in rat and mouse identified a number of stimuli or
environmental conditions that alter expression of selected mRNAs
in immature, or mature brain, in conjunction with–often bi-
directional–changes in CpG methylation of the corresponding
promoters [8,9,39,40]. The conclusion drawn by these studies,
either explicitly or implicitly, is that neuronal gene expression is
subject to epigenetic regulation. However, most CNS tissues,
including cerebral cortex, are comprised of a highly heterogeneous
mixture of various dividing and postmitotic cell populations, which
are likely to show important differences in the methyl-CpG
patterning of their genomes. This uncertainty regarding the
cellular specificity of any DNA methylation signal obtained from
brain homogenates places limitations on the interpretation of the
age-related changes in methylation as described above. Nonethe-
less, the presence of DNMT3a in cortical neurons across a wide
age range (Fig 4), in conjunction with the robust, age-related
methylation changes at .50% of the gene loci (Fig. 1, 2), strongly
suggests an ongoing modification of the neuronal DNA long after
the exit from the cell cycle, which in primate cerebral cortex
occurs during fetal mid-development [41]. To find out whether
DNA methylation is dynamically regulated in postmitotic neurons
and to rule out the potential confound of changes in glia numbers
during the course of development [42,43], we isolated nuclei of
differentiated neurons from child and adolescent (1–16 years) and
aged (.60 years) cortex using NeuN immunolabeling in conjunc-
tion with fluorescence-activated cell sorting (FACS) (Fig. 5A,B).
Then, the methylation levels for 10 gene loci were analyzed in the
neuronal DNA by MethyLight PCR. When compared to child
and adolescent specimens, DNA from aged neuronal nuclei
showed a significant increase in methylation at 3/10 loci (HOXA1,
PGR, SYK), and a significant decrease in 1/10 loci (S100A2)
(Fig. 5C). Therefore, during the transition from childhood to old
age, differentiated cortical neurons undergo bidirectional changes
in DNA methylation.
DISCUSSION
The present study examined DNA methylation changes for 50
genomic loci during the course of development, maturation and
aging of the human cerebral cortex. The majority of loci showed
significant age effects: eight loci showed a progressive increase in
methylation that continued across the entire lifespan and another
18 loci were defined by a sharp rise within the first months or years
after birth. We present direct evidence that, for a subset of loci,
genomic DNA from differentiated cortical neurons undergoes
methylation changes during the course of maturation and aging.
In addition, one locus, MGMT, showed a stochastic accumulation
in methylation starting around age 50, with potential implications
for the tumor biology of astrogliomas, as discussed above. While
DNA methylation changes related to development or aging were
extremely robust in the present study, disease-associated changes,
on the other hand, were surprisingly limited. Schizophrenia,
a chronic psychiatric disease condition associated with psychosis
and widespread cortical dysfunction in the absence of large-scale
loss of neurons [44,45,46], was not associated with significant
methylation changes in the present study. On the other hand,
cases diagnosed with Alzheimer’s disease, which is defined by
a neurodegenerative process in cerebral cortex and other brain
regions, showed significant methylation changes in 2/50 loci. One
locus (S100A2), which is methylated in neurons (Fig. 5C) was
significantly less methylated in the DNA from Alzheimer cases
compared to age-matched controls (Fig. 3), possibly due to large-
Figure 3. Acceleration of age-associated DNA methylation changes in
Alzheimer’s disease. Scatter plots showing age-associated methylation
changes for SORBS3 and S100A2 across all ages. N=125 subjects,
including Alzheimer subjects (red squares), schizophrenics (blue
triangles) and controls (green dots). P-values refer to T-tests for
comparison of Alzheimer subjects versus all other subjects older than
60 years. One outlier (ID 2763, 104 years old, Table S4) was omitted
from the age-associated analyses.
doi:10.1371/journal.pone.0000895.g003
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methylation of another locus (SORBS3) was higher in the
Alzheimer samples than in controls. Thus, the DNA methylation
alterations in both genes appear to reflect an enhancement, or
acceleration, of the age-associated changes that we observed in
normal brain (Fig. 3).
It is noteworthy that the overwhelming majority of loci analyzed
in the present study demonstrated age-related increases in DNA
methylation in cerebral cortex (26/50 loci), and only one gene–
S100A2–showed a change in the opposite direction; this decrease
was even more pronounced in the Alzheimer’s cohort. Likewise, in
DNA samples derived selectively from differentiated neurons of
controls, only S100A2 showed an age-related loss of methylation,
while significant increases were found for 3/10 genes (Fig. 5C).
Collectively, these findings support the notion that DNA
methylation levels progressively increase in the cerebral cortex
at many genomic loci during the course of maturation and
aging. On the other hand, according to the findings presented
here, DNA de-methylation events appear to play a less prominent
role. Therefore, it remains to be clarified whether or not there is
active de-methylation in brain, and if DNA repair-related
mechanisms are involved similar to those recently reported for
dividing cells and Xenopus oocytes [47]. Additionally, further
studies will be required in order to determine whether or not DNA
methylation/demethylation in human brain is subject to more
acute alterations—on the scale of hours or days—as has been
previously demonstrated in cell cultures and animal models
[39,40,48].
It is important to realize that our study had several limitations,
including the focus on one area of the cerebral cortex, i.e. the
neocortex of the anterior and lateral temporal lobe. Therefore,
additional studies will be necessary to confirm that the develop-
mental DNA methylation changes as observed in this study are
a generalized feature operating throughout all areas of the human
cerebral cortex. Furthermore, we monitored DNA methylation
changes at a limited number of genomic sequences, hence it will be
necessary to confirm the findings reported here on a more
comprehensive, genome-wide scale. Such studies will be necessary
in order to find out (i) whether or not the developmental DNA
methylation changes reported here represent a more generalized,
age-dependent drift towards increased methylaton levels and (ii)
whether or not schizophrenia or Alzheimer’s disease are associated
with DNA methylation changes affecting wide-spread portions of
the genome. Finally, while our study presents some of the first and
direct evidence for methylation changes in the DNA of terminally
differentiated neurons, our analyses was limited to samples
obtained from children and adults, because isolation of neuronal
nuclei from fetal specimens via FACS was not feasible for technical
reasons. Hence, it remains to be determined whether or not
neurons, or various types of glia and other non-neuronal cells,
contribute to the observed sharp rise in DNA methylation during
the perinatal and early childhood period that was observed at 18/
50 loci in this study. These highly dynamic methylation increases
postnatally could either be related to the relatively high levels of
neuronal DNMT3a methyl-transferase in the immature brain [36]
or , alternatively, result from developmental shifts in cell
Figure 4. Developmental and cellular expression pattern of DNMT3a in the cerebral cortex. (A) Representative immunoblotting of temporal cortex
homogenates with anti-DNMT3a antibody (top) and b-actin as loading control (bottom). Left, fetal samples (gw=gestational week); right, child and
adult brains (yrs=years) and, as positive control, murine embryonic carcinoma, ‘‘P19’’ cells. Notice expression of DNMT3a—indicated by a ,120 kDa
band—across all ages. (B, C) Digitized images of temporal cortex nuclei from 1 year old infant, processed for DNMT3a (red) and NeuN (green)
immunoreactivity and counterstained with DAPI. Notice numerous neuronal nuclei expressing both markers, including representative example
marked by arrowhead. Occasional non-neuronal DNMT3a+ nucleus is marked by arrow. (D,E) show weak background staining and formalin fixation-
related autofluorescence in negative controls processed without primary antibodies. (F–H) Images from layers III, IV and V of parallel sections from
adult temporal cortex, stained for Nissl (F) or hybridized with digoxigenin-labeled DNMT3a antisense (G) or sense riboprobe (H). Notice in (G) robust
expression of DNMT3a mRNA in a subset of layer III and V neurons. Images in B–E taken at with 206objective. Bar (F–H) in H=100 mm.
doi:10.1371/journal.pone.0000895.g004
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of oligodendrocytes and other glia-related changes [49]. In light of
these findings, it is tempting to speculate that certain nurturing,
feeding and other ‘‘environmental’’ conditions could potentially
result in sustained DNA methylation and gene expression changes
affecting many parts of the genome. Indeed, emerging evidence
from animal models is in support of this hypothesis [9,50]. Based
on the results of the present study, we predict that approximately
one half of genes encoded in the genome will show age-related
DNA methylation changes in the human brain, many of which will
directly, or indirectly, affect neuronal gene expression and thus
cognition and behavior.
MATERIALS AND METHODS
Human brain tissue
Fresh frozen, postmortem brain tissue from fetuses, newborns and
children were obtained through the Brain and Tissue Banks for
Developmental Disorders, University of Maryland and University
of Miami (NICHD contract # NO1-HD-8-3284). Adult tissue
samples were obtained from three brain banks (i) the Center for
Neuroscience, University of California at Davis, CA, (ii) the
Harvard Brain Tissue Resource Center at McLean Hospital,
Belmont, MA, and (iii) the Massachusetts General Hospital,
Boston, MA. All brain banks provided tissue to us without personal
identifiers, and all collection and written consent procedures
(donors or family members) were approved by the institutional
review boards of the brain banks’ institution. Small blocks of
frozen, unfixed tissue were dissected from the developing cortical
plate (fetus) or cerebral cortex (children, adults) of the anterior
lateral temporal lobe.
Altogether, 17 fetal, 15 child and 93 adult specimens were
included in the present study. Among the adult samples, there
were 18 cases meeting CERAD criteria of definite Alzheimer’s
disease and 30 cases meeting DSM-IV based criteria for
schizophrenia (Table S4).
Methylation and mRNA analyses
From all specimens, DNA was extracted from the cortical plate
(fetus) or gray matter (children, adults) using a standard procedure,
with modifications [51] and analyzed by MethyLight PCR after
bisulfite conversion [22,23,52] (for primer sequences, see Table
S2). In addition, RNA was extracted from cortical gray matter of
child and adult samples with the RNeasy Lipid Tissue Mini Kit
(Qiagen, Valencia, CA) and treated with DNAse I. RNA quality
for all samples was assessed using high-resolution capillary
electrophoresis on the Agilent Bioanalyzer 2100 (Agilent Tech-
nologies, Palo Alto, CA). Samples with a RIN,4.0 were discarded
[27]. RNA was reverse-transcribed and amplified with TaqMan
One-Step RT-PCR Master Mix Reagent in 7500 Real Time PCR
System machine (Applied Biosystems, Foster City, CA, U.S.A.), in
conjunction with unlabeled primers and SYBR Green (GAD1)o r
FAM-labeled primer sets purchased from Applied Biosystems (all
other genes). Quantifications were performed by positioning the
cycle threshold within the linear range of amplification curve.
Each value of mRNA was calculated with the equation
V=(1+E)
Ct (E: amplification efficiency) and normalized to 18S
ribosomal RNA.
DNMT3a expression studies
For western blotting, 100 mg aliquots of cortical tissue were
homogenized in 16 Laemmli buffer for SDS-PAGE, then
processed for anti-DNMT3a immunoreactivity (rabbit polyclonal,
Abcam Inc., Cambridge, MA) at a final dilution of 1:250; or, for
loading control, mouse anti-b-actin (Sigma, St. Louis, MO), final
dilution 1:10,000.
To extract nuclei for DNMT3a-like immunolabeling, cortical
tissue was homogenized in 2mL 16RSB buffer (100 mM NaCl,
30mM MgCl2, 100 mM Tris-HCl, pH 7.5) with 1% NP-40,
Figure 5. Age-related DNA methylation changes in differentiated
neurons. (A) Examples of nuclei stained with anti-NeuN (green) and
counterstained with DAPI; arrowhead marks double-labeled cell. Notice
absence of detectable background and autofluorescence in these
samples that were processed without prior fixation (B) Representative
FACS of unfixed NeuN labeled material similar to the one shown in (A)
(top) and of negative control (bottom); blue dots mark sorted neuronal
nuclei (NeuN+). (C) Heatmap showing methylation levels of neuronal
DNA isolates for 10 different genes across the lifespan (range: 0.6–
97 years). Each gene is grouped into quartiles (blue=1 low, green=2
medium-low, yellow=3 medium high, red=4 high extent of methyl-
ation). The larger the number of samples with no detectable
methylation, the fewer the number of observations coded green and
yellow. White space=no data. *=p,0.05 , Mann-Whitney U permuta-
tion based on comparison of immature/young (0.6–16 years) to old
(62+years) samples. Notice that neuronal DNA from advanced age
group shows significant increase in DNA methylation for 3/10 gene loci
(PGR, SYK, HOXA1), but decreased levels at S100A2 locus.
doi:10.1371/journal.pone.0000895.g005
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rotor at 10006g for 10 min at 4uC. Subsequently, the pellet was
dissolved in 4 mL 4% phosphate-buffered paraformaldehyde
(PFA) and incubated for 10 min at room temperature. This
homogenate was layered onto a 30% sucrose cushion, centrifuged,
and the resulting pellet dissolved in 0.1% Triton X-100/0.32M
sucrose/5 mM CaCl2/0.1 mM EDTA/10 mM Tris-HCl,
pH 8.0, mixed with 1 mL 1.8 M sucrose, and centrifuged at
15006g at 4uC for 10 min on a 1 mL 1.2 M sucrose cushion.
Nuclei pellets were dissolved in 16PBS, and then dried on glass
slides and blocked with 16PBS/10% normal goat serum/0.2%
Triton X-100 for 1 hour. For double immunolabeling, primary
antibodies (anti-DNMT3a and anti-NeuN as a neuron-specific
marker [53,54]) were labeled with the Zenon Alexa Fluor 594
Rabbit IgG Labeling Kit or the Enhanced ZenonH (Alexa 488)
Mouse IgG Labeling Kit (Invitrogen, Carlsbad, CA) and applied
at 1:500 final dilution to the slides for 4 hrs. Following incubation,
slides were rinsed repeatedly, incubated in tyramide solution
according to the manufacturer’s instructions, washed, counter-
stained with DAPI and coverslipped.
To prepare for in situ hybridization histochemistry, tissue blocks
were allowed to thaw, then immersion-fixed with 4% phosphate-
buffered PFA for up to 4 days, and then cryoprotected in 30%
phosphate-buffered sucrose; 20 mm sections were cut on a cryostat,
mounted on glass slides, and stored at 280uC until use. Sense and
antisense digoxigenin (DIG)-labeled DNMT3a cRNA probes were
generated from full-length human DNMT3a cDNA (Genbank
BC043617) in the presence of DIG-11-UTP (Roche Applied
Science, Indianapolis, IN), according to the manufacturer’s
instructions. Templates were digested with DNase I and the
cRNA purified by LiCl precipitation. Sections were treated with
0.2 M HCl and then acetylated with 0.25% acetic anhydrate in
0.1 M triethanolamine, and prehybridized with hybridization
buffer (50% formamide, 26SSC, 10% dextran sulfate, 0.5 mg/ml
sperm DNA, 0.25 mg/ml yeast tRNA, 0.2 mg/ml BSA, 50 ug/ml
Heparin, 2.5 mM EDTA and 0.1% Tween-20) at 60uC for 1 hr.
Sections were then hybridized with DIG-labeled probes diluted
1:50 in hybridization buffer (50 ml/section) at 60uC overnight.
Sections were washed with 26SSC at R.T., 1XSSC at 37uC and
then treated with RNase A at the same temperature. After RNase
A digestion, sections were washed sequentially with 16SSC at
37uC, 16SSC: 50% formamide at 52uC, 0.16SSC at 52uC and
then developed with the DIG Nucleic Acid Detection kit (Roche
Applied Science, Indianapolis, IN), in conjunction with sheep anti-
digoxigenin-alkaline phosphate conjugated antibody (1:1000)
(Roche) and NBT/BCIP chromogen (1:50) (Roche) according to
the manufacturer’s instructions. Sections were mounted with
mounting medium (VetctaMount
TM AQ, Vector Laboratories,
Burlingame, CA) and coverslipped with glass.
Flow cytometry
Intact nuclei were prepared from up to 3 gram of frozen-thawed
tissue as described above, with the exception of the fixation step,
and further purified by ultracentrifugation through a sucrose
cushion at 25,0006g for 2.5 hrs at 4uC. The pelleted nuclei were
dissolved in 1 mL 16PBS, centrifuged for 5 min at 14,0006g , and
the nuclei pellets stored at 280uC until further processed. Nuclei
were immunolabeled with anti-NeuN antibody (see above) and
sorted using a FACSVantage DiVa system (BD Biosciences), the
DNA extracted and processed by Methylight PCR as described
above.
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